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Abstract
Introduction Fluenz Tetra is an intranasal quadrivalent
live attenuated influenza vaccine (QLAIV) and is recom-
mended as the vaccine of choice for children in the
2014/2015 influenza season vaccination programme in the
UK.
Objective The primary objective of the study was to
estimate the crude incidence rate of adverse events of
interest (AEIs) following vaccination with the nasal
QLAIV early in the 2014/2015 influenza season in children
and adolescents in England.
Methods A pilot non-interventional cohort post-authori-
sation safety study (PASS) was conducted during the
2014/2015 influenza season in England. Vaccinees were
recruited via the mass vaccination programme in England.
Participant outcomes, validated by a healthcare profes-
sional (general practitioner) where appropriate, were cap-
tured through questionnaires (surface mail, telephone,
e-questionnaire). Data analysis comprised descriptive
statistics and calculation of event risks and incidence rates,
stratified by age group and selected co-morbidities.
Results The final evaluable cohort consisted of 385 par-
ticipants; the median (interquartile range) age was 4
(3–9) years with a range of 2–17 years, and 53.2 % were
female. The most frequently reported AEI was nasal con-
gestion (n = 167; 43.4 %; 312.3 per 1000 patient-weeks
[95 % CI 267.3–364.8]). Further frequently reported AEIs
were malaise (n = 87; 22.6 %; 123.4 per 1000 patient-
weeks [95 % CI 98.9–154.1]) and cough (n = 80; 20.8 %;
118.5 per 1000 patient-weeks [95 % CI 95.1–147.8]). Five
hypersensitivity-type reactions were reported, although on
follow-up none were true hypersensitivity reactions or
required hospitalisation. No serious adverse events (SAEs)
were reported, with no hospitalisations or deaths. No sig-
nificant change in reactogenicity or other apparent safety
signals was detected as part of this study.
Conclusion The pilot study showed no significant change
in reactogenicity or other apparent safety signals from the
data collected. Continued enhanced surveillance of sea-
sonal influenza vaccines will ensure their ongoing safety
for the prevention of serious illness from seasonal influenza
outbreaks.
Key Points
Frequently reported adverse events of interest after
administration of nasal quadrivalent live attenuated
influenza vaccine were nasal congestion, malaise and
cough.
No serious adverse events were reported during this
study.
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1 Introduction
Fluenz Tetra (Marketing Authorisation Holder (MAH):
MedImmune LLC, Netherlands) is a quadrivalent live
attenuated influenza vaccine (QLAIV) administered by the
intranasal route and supplied in an applicator that allows a
divided dose to be administered in each nostril. The device
allows intranasal vaccination to be performed without the
need for additional training. Neither dose needs to be
repeated if the patient sneezes or blows their nose fol-
lowing administration [1]. The Joint Committee on Vac-
cination and Immunisation (JCVI) recommended that
Fluenz Tetra be used as the vaccine of choice for children
in the 2014/2015 flu season vaccination programme in the
UK [2].
In April 2014, the European Medicines Agency (EMA)
issued interim guidance on enhanced safety surveillance
for seasonal influenza vaccines in the EU [3]. This
guidance was issued to outline principles to be followed
for improved continuous routine surveillance and to
rapidly detect any increased local and systemic adverse
events of interest (AEIs) or other unexpected adverse
immune response that may arise during the influenza
vaccine product life-cycle. In response to the guidance, a
pilot active safety surveillance study was conducted as a
non-interventional cohort post-authorisation safety study
(PASS) for one particular influenza vaccine. The vaccine
investigated, nasal QLAIV, marketed as Fluenz Tetra in
the UK, is licensed for use in children and adolescents
between the ages of 2 and 17 years, except in those where
contraindications or special warnings and precautions for
use apply. An expedited safety summary report was
required as part of this guidance, with interim results
available for review 1 month after first vaccination. For
this reason, studies using secondary data sources would
not be appropriate due to the time lag in availability of
such data.
The primary objective of the study was to estimate the
crude incidence rate of AEIs following vaccination with
the nasal QLAIV early in the 2014/2015 influenza season
in children and adolescents in England. The AEIs listed as
part of the EMA guidance and pertinent to QLAIV
include fever, vomiting and nausea, malaise, headache,
irritability and crying (for under 5-year-old vaccinees),
decreased appetite, rash, mylagia, events indicative of
allergic and hypersensitivity reactions, nasal congestion,
wheezing, oropharyngeal pain, cough and epistaxis. Sec-
ondary study objectives included the characterisation of
patients vaccinated with nasal QLAIV, the quantification,
description and classification of reported AEIs, and the




In total, 23 general practitioner (GP) practices, 17 primary
schools and six high schools across England took part in
the study. Recruitment opened on 30 September 2014 and
closed on 19 December 2014. Study participants were
vaccinated with QLAIV between 30 September 2014 and
11 December 2014. A full study database lock was
implemented on 2 January 2015 to permit receipt of
responses from vaccines consented at the end of the
recruitment period.
Figure 1 depicts how participants were recruited to the
study through the mass vaccination programme imple-
mented in GP practices and also through schools involved
in the pilot vaccination scheme.
Eligible participants were children and adolescents aged
2–17 years administered with QLAIV (exposure) at par-
ticipating vaccination sites. Vaccinees with co-morbidities,
who take medication, or who received additional vaccines
on the same day or within 1 month of receiving QLAIV
were included since this was an observational cohort study
conducted in a naturalistic setting. The target number of
consented vaccinees was 200 vaccinees per age group, i.e.
(i) 2–4 years; (ii) 5–10 years; and (iii) 11–17 years to give
a target total of 600 consented vaccinees. This was to
ensure that a minimum of 100 vaccinees, with completed
data, per age group was reached, allowing for participants
lost to follow-up and withdrawal of consent. The rationale
for this sample size was based on the information provided
within the interim guidance on enhanced safety surveil-
lance [3], which requested 100 participants within each age
group.
2.2 Ethical and National Health Service Approval
The Proportionate Review Sub-committee of the West of
Scotland 5 Research Ethics Committee (REC) gave a
favourable opinion for the conduct of the study (REC
reference: 14/WS/1067) and the study was also adopted by
the UK National Health Service (NHS) National Institute
for Health Research (NIHR) Clinical Research Network
(CRN). In addition, appropriate local NHS Research and
Development permissions were granted before the study
commenced.
2.3 Outcome Data
Variables assessed were derived from the responses by
vaccinees or their representatives on informed consent
forms, enrolment questionnaires and day 14 questionnaires
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(Electronic Supplementary Material 1). Participant data on
demographics (age, sex), date of vaccination, relevant co-
morbidities, medication, changes to medication or new
medication within the 14 days post-vaccination, reported
targeted AEIs (outcome), date of onset, date of resolution
and other adverse events (outcome) were collected. Events
were not validated by a healthcare professional unless
further information was required. As shown in Fig. 1,
follow-up information could be obtained either from the
participant after receipt of their day 14 data or with their
GP using a standard follow-up questionnaire or a telephone
call.
All information on the e-questionnaires completed on
the bespoke study website (via web-portal) was automati-
cally transferred to a Drug Safety Research Unit (DSRU)
database. Information completed on paper questionnaires
was entered onto the DSRU database by suitably trained
data entry/coding DSRU staff. Events collected as free-text
were coded onto the database using the MedDRA dic-
tionary. Analyses were performed using STATA version
12 (StataCorp, College Station, TX, USA).
2.4 Data Analysis
Data were summarised using univariate descriptive statis-
tics, including measures of central tendency and dispersion
for continuous variables (mean, standard deviation [SD],
median, range and percentiles) and frequencies with pro-
portions for categorical variables. The continuous variable
of age (at vaccination) was categorised into age groups
Fig. 1 Flow diagram
illustrating the study design and
the involvement of study
participants. DSRU Drug Safety
Research Unit, GP general
practitioner, ICF informed
consent forms, PIS participant
information sheets, SAEs
serious adverse events
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(2–4, 5–10 and 11–17 years). Adverse event of interest
incidence risks were calculated with 95 % exact binomial
confidence intervals (CIs). Person-time at risk for each
event was calculated, along with incidence rates per 1000
patient-weeks and the 95 % exact Poisson CI. Stratification
of AEI risks and rates was performed by age group and by
medical condition, where appropriate. Since participants
were asked to provide information on new symptoms,
events were assumed to be incident reports post-
vaccination.
An assessment of missing information for all key vari-
ables on paper questionnaires was conducted during the
data analysis stage to determine the distribution of miss-
ingness and whether there was pattern of missingness that
showed any dependency on age group. A sensitivity anal-
ysis was planned a priori to examine the impact of missing
data on estimates of risk and incidence rates if proportion
of missingness was greater than 20 %. Since this was a
pilot study, and given the small sample size, it was decided
that methods to handle missing data would not be appro-
priate unless there was a very large amount of missing data.
Questionnaires completed online did not have missing data
as the participant was prompted to complete each field
before moving onto the next.
3 Results
3.1 Cohort Characteristics
Participant recruitment is summarised in Fig. 2. The final
evaluable cohort comprised 385 participants (see Table 1
for characteristics of the evaluable cohort).
An assessment of the level of missing data was carried
out on the evaluable cohort. No more than 5 % of data
were missing for any main question or sub-question on the
questionnaires (data not presented). Therefore, no sensi-
tivity analysis was conducted.
The median age of the evaluable cohort was 4 years,
with an interquartile range (IQR) of 3–9 years. The median
age for females was 5 years (IQR 3–9 years) and for males
was 4 years (IQR 3–9 years). There were 205 (53.2 % of
cohort) females and 180 (46.8 % of cohort) males in the
evaluable cohort.
Five vaccinees had additional vaccinations on the
same day as receiving QLAIV (Fluenz Tetra) and a
further five vaccinees reported receiving an additional
vaccine or additional vaccines within 1 month of
receiving QLAIV (Fluenz Tetra). These vaccinations
were the MMR (mumps, measles and rubella), 4-in-1
Preschool Booster (DTaP/IPV [diphtheria, tetanus, per-
tussis, inactivated polio) and HPV (human papilloma
virus) vaccine.
Of the total evaluable cohort, 85 participants reported
that the vaccinee had pre-existing asthma, with only two
participants having pre-existing diabetes mellitus, two with
pre-existing heart disease, one with pre-existing chronic
kidney disease and one with pre-existing immunosuppres-
sion. Participants reported that 92 (23.9 %) of the evalu-
able cohort take prescribed or over-the-counter
medications, the majority of which were to treat respiratory
conditions: 66 of 92 receiving salbutamol (Anatomical
Therapeutic Chemical [ATC] Drug Class R03AC) and 42
of 92 receiving beclometasone dipropionate (ATC Drug
Class R03BA]). This correlates to the high proportion of
the evaluable cohort who reported having pre-existing
asthma. Five participants reported a change to their medi-
cation in the 14 days post-vaccination.
The study was designed to capture the events experi-
enced by children and adolescents following their first
vaccination with QLAIV (Fluenz Tetra). When questioned,
GP practices indicated that only a very small proportion of
vaccinees or no vaccinees received two doses of QLAIV
(Fluenz Tetra). The highest proportion of those vaccinated
receiving two doses at any one GP practice was 3.5 % (14/
400) of the total vaccinated with QLAIV (Fluenz Tetra),
with the majority of practices indicating that only two or
three children received two doses. No participants indi-
cated on their questionnaire in the free-text event section
or anywhere on the paper version that they received a
second dose of QLAIV (Fluenz Tetra) or that they expe-
rienced any events following a second dose of QLAIV
(Fluenz Tetra).
3.2 Adverse Events of Interest
The total number of AEIs reported in the evaluable cohort
was 650 in 237 participants. Targeted AEIs are summarised
in Table 2 and other events are summarised in Table 3.
The most frequent AEI across the whole evaluable cohort
was nasal congestion (n = 167; 43.4 %). Furthermore,
more than 20 % of the cohort reported AEIs of malaise
(n = 87; 22.6 %) and cough (n = 80; 20.8 %). In contrast,
less than 5 % of the cohort reported AEIs of wheezing
(n = 9; 2.3 %), nosebleed (n = 9; 2.3 %), rash (n = 8;
2.1 %) and hypersensitivity-type reactions (n = 5; 1.3 %).
Four of the five vaccinees who received additional
vaccines on the same day as QLAIV reported experiencing
AEIs within the observation period (high temperature
n = 3, malaise n = 3, decreased appetite n = 3, muscle/
joint pain n = 1, wheezing n = 4, nasal congestion n = 4,
mouth/throat pain n = 3, cough n = 1, increased irri-
tability n = 4, increased crying n = 2).
In total, five counts of hypersensitivity-type reactions
were recorded in five separate patients, but on follow-up
none were true hypersensitivity reactions. Follow-up
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information indicated that four of the five participants
described ‘‘feeling dizzy’’ or ‘‘light headed’’ post-vacci-
nation which quickly resolved, hence their reason for
ticking yes to the question ‘‘Did the vaccinee experience
any of the following: swelling of the face, lips or tongue,
difficulty breathing, feeling of dizziness/light-headedness,
general itchiness with a rash’’.
Crude incidence risks and rates for AEIs were calculated
for each age group and are presented in Table 4. Total time
at risk is the denominator of person-time at risk censored at
the time of the AEI.
Events with crude incidences highest in the 2–4 years
age group compared with other age groups were nasal
congestion (346.4 per 1000 person-weeks [95 % CI
280.1–428.5]) and decreased appetite (91.2 per 1000 per-
son-weeks [95 % CI 63.8–130.5]). Crude incidence rates
highest in the 11–17 years age group compared with other
age groups were nausea and vomiting (40.4 per 1000 per-
son-weeks [95 % CI 18.2–90.0]) and headache (127.9 per
1000 person-weeks [95 % CI 78.3–208.7]). In addition to
nausea and vomiting and headache, crude incidence rates
of generally feeling unwell (malaise), mouth and throat
pain and wheezing increased with age. AEIs for which the
rate consistently decreased with age included high tem-
perature and cough.
In addition to the targeted event reports, a total of 35
‘‘other’’ non-targeted events were reported in 26 partici-
pants. Seven counts of tiredness (preferred term [PT] fati-
gue) were reported in the evaluable cohort and seven
events were reported as classified within the gastrointesti-
nal disorders System Organ Class (SOC) (PTs: diarrhoea,
mouth ulceration, abdominal pain upper, anal inflamma-
tion, chapped lips, dysphagia). One participant reported
experiencing flu symptoms post-vaccination. One partici-
pant experienced a rash that was described as ‘‘blister like
spots’’ and coded as a MedDRA PT of ‘‘blister’’ on the
day of vaccination.
There were no reported pregnancies during the course of
the study. There were also no deaths reported during the
course of the study.
In terms of serious adverse events (SAEs) or important
medical events, none were recorded during the course of
the study. Additionally, no events reported are listed as
potential risks in the Risk Management Plan (RMP).
Stratification of incidence risks and rates of AEIs by
medical condition was performed (data not presented).
Results were stratified for participants with and without
asthma (Electronic Supplementary Material 2, Supple-
mentary Table 1) as 22 % (n = 85) of the evaluable cohort
indicated they had the condition. Incidence rates of
Fig. 2 Flow of participant
recruitment. ICF informed
consent forms
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wheezing were approximately 30 times higher in the
asthma group (50.1 per 1000 patient-weeks [95 % CI
25.1–100.2]) than in participants without asthma (1.7 per
1000 patient-weeks [95 % CI 0.2–11.9]).
Furthermore, upon examination of batch effects on the
counts of AEIs, no definitive pattern or clustering of AEIs
per batch in the 14 different batches recorded for vaccinees
with AEIs was visible (data not presented).
4 Discussion
This pilot study has enabled the collection of important
safety data from participants vaccinated with QLAIV
(Fluenz Tetra) within GP practices and schools in pilot
areas across England. The study fulfils the regulatory
objectives for enhanced safety surveillance for seasonal
influenza vaccines in the early detection of selected events
of interest.
The most frequently reported AEI across all age groups
within this study was nasal congestion, a very common
adverse effect (frequency C1 in 10) according to the
Summary of Product Characteristics (SmPC) [1]. Other
frequently reported AEIs were malaise and decreased
appetite, which are also specified as very common in the
SmPC [1]. Cough, a common AEI within this study, on the
other hand, does not feature in the SmPC. However, in a
randomised double-blind non-inferiority study of QLAIV
in 1200 subjects aged 18–49 years, cough was reported by
13.6 % of the safety cohort within 14 days post-vaccina-
tion with nasal QLAIV [4]. Within this same study, runny/
stuffy nose (43.6 %) was the most frequently reported
symptom within the safety cohort 14 days post-vaccination
[4]. In a further study of QLAIV in the USA using the
Vaccine Adverse Event Reporting System (VAERS), 8 %
of all 599 spontaneous reports in 2- to 17-year-olds were
reports of cough [5]. Studies of the trivalent LAIV
demonstrated similar patterns of AEIs, with nasal conges-
tion (also referred to as runny nose or rhinorrhoea) being
the most frequently reported AEI among children [6, 7] as
well as adolescents and adults [8].
All five reported events of hypersensitivity-type reac-
tions within this study were not deemed to be true hyper-
sensitivity reactions, with vaccinees reporting symptoms of
‘‘dizziness’’ or ‘‘light-headedness’’ upon follow-up. The
wording of the question on the day 14 questionnaire may
have been misleading as it did not explicitly ask for
symptoms corresponding to an allergic response, but any of
the following: ‘‘Swelling of the face, lips or tongue, diffi-
culty breathing, feeling of dizziness/light-headedness,
Table 1 Characteristics of the
evaluable cohort (N = 385)
Characteristics Evaluable cohort
Male, n (%) 180 (46.8)
Median age, years (IQR) 4 (3–9)
Other vaccinations, n (%)
Other vaccinationsa on the same day as QLAIV 5 (1.3)
Other vaccinationsb within 1 month prior to QLAIV 5 (1.3)
Pre-existing medical conditions, n (%)
Asthma 85 (22.1)
Diabetes mellitus 2 (0.5)
Heart disease 2 (0.5)
Chronic kidney disease 1 (0.3)
Immunosuppression 1 (0.3)
Moderate/severe liver disease 0 (0.0)
Blood disorder 0 (0.0)
Medication, n (%)
Vaccinees taking medicationc at time of vaccination 92 (23.9)
Changes to medicationd following vaccination 5 (1.3)
DTaP/IPV diphtheria, tetanus, pertussis, inactivated polio, HPV human papilloma virus, IQR interquartile
range, MMR mumps, measles and rubella, QLAIV quadrivalent live attenuated influenza vaccine
a 4-in-1 Pre-School Booster (DTaP/IPV), MMR (second dose)
b 4-in-1 Pre-School Booster (DTaP/IPV), MMR (second dose), HPV
c The 5 most frequently reported medications were salbutamol, beclometasone dipropionate, fluticasone
propionate/salmeterol, montelukast and fluticasone propionate
d All changes were new medications: antibacterials, salbutamol, beclometasone dipropionate and macrogol
laxative
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general itchiness with a rash’’. Hypersensitivity-type
reactions have been rarely reported with live attenuated
influenza vaccines (LAIV). A single event of bron-
chospasm was reported following vaccination with the
tetravalent LAIV (TLAIV) [4]. Furthermore, a single report
of ‘‘allergy’’ within VAERS in 2- to 17-year-olds vacci-
nated with QLAIV was identified, which was a non-ana-
phylaxis allergic reaction, as well as a single report of
anaphylaxis within 18- to 49-year-olds [5]. Five reports of
‘‘allergy’’ within VAERS in 2- to 17-year-olds vaccinated
with trivalent LAIV included three reports of anaphylaxis
and two non-anaphylaxis allergic reactions [5], and five
reports in 18- to 49-year-olds included two reports of
anaphylaxis and three non-anaphylaxis allergic reactions
[9].
No SAEs or important medical events were reported
during the course of the study and no events were con-
sidered to be important identified or potential risks.
Spontaneous reports within VAERS showed similar results,
with no concerning safety patterns relating to QLAIV
vaccination [5].
A large number of study participants reported having
asthma, which is a special warning/precaution for use
within the SmPC, which states that QLAIV (Fluenz Tetra)
should not be administered to children or adolescents with
severe asthma or active wheezing because these individuals
have not been adequately studied in clinical studies [1].
Severe asthma or active wheezing was not reported as a
free-text event as being present at the time of vaccination
or following vaccination. The high incidence rates of
wheezing within the asthma group following vaccination
are potentially a result of the aetiology of disease and not
the vaccination. The use of the vaccine within asthmatic
children has been reported in other studies [5].
This active surveillance study enabled the successful
monitoring of safety of seasonal influenza vaccines.
Questionnaires were completed well online, and there were
minimal missing data on paper questionnaires. Similar
methodologies have also been utilised successfully in other
countries. In New Zealand, telephone surveys were used to
successfully evaluate febrile events following vaccination
of individuals from 184 GP surgeries with five different
influenza vaccines [10]. An Australian study used web-
based surveys to explore a number of AEIs following
vaccination of individuals from 15 GP surgeries with five
different influenza vaccines [11]. Response rates for this
web-based survey (61 %) were similar to the response rates
within the online questionnaire group within our study
(66.2 %) [11]. The study enabled information on AEIs to
be captured directly from vaccinees, hence capturing AEIs
that are not medically attended or reported to the GP.
The cohort involved in this study is thought to be rep-
resentative of the population vaccinated with QLAIV
(Fluenz Tetra) during the 2014/2015 influenza season.
Participants were recruited from a good geographical
spread of GP practices across England as well as from
Table 2 Number and incidence
rates of cases of adverse events
of interest in the evaluable
cohort (N = 385)
Targeted adverse event of interest n (%) Incidence rate per 1000
patient-weeks (95 % CI)
High temperature (i.e.[38.0 C) 41 (10.7) 55.2 (40.3–75.5)
Nausea and vomiting 21 (5.5) 24.3 (15.3–38.5)
Generally feeling unwell (malaise) 87 (22.6) 123.4 (98.9–154.1)
Headache 38 (9.9) 49.3 (35.4–68.6)
Decreased appetite 53 (13.8) 68.4 (51.4–91.0)
Rash 8 (2.1) 9.2 (4.4–19.4)
Muscle pain or joint pain 22 (5.7) 25.7 (16.4–40.3)
Any of the following: swelling of the face, lips or tongue,
difficulty breathing, feeling of dizziness/light-headedness,
general itchiness with a rash
5 (1.3) 6.6 (2.7–15.8)
Wheezing 9 (2.3) 11.9 (6.2–22.8)
Nasal congestion/runny nose 167 (43.4) 312.3 (267.3–364.8)
Mouth or throat pain 39 (10.1) 47.4 (33.8–66.3)
Cough 80 (20.8) 118.5 (95.1–147.8)
Nosebleed 9 (2.3) 11.9 (6.2–22.9)
Increased irritability (if the child is between 2 and 4 years) 44 (22.8) 121.4 (88.4–166.9)
Increased crying (if the child is between 2 and 4 years) 27 (14.0) 66.9 (44.4–100.7)
Total 650
CI confidence interval
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primary and high schools in selected pilot areas. The cohort
included both female and male children and adolescents
with co-morbidities in the age range 2–17 years. Open
inclusion criteria within this study allowed the investiga-
tors to gain an understanding of the safety of the vaccine in
a naturalistic setting.
This study is a pilot and will enable, in conjunction with
other studies, the refinement of the thinking and method-
ologies of seasonal influenza vaccine safety surveillance. In
future work, continued safety surveillance of seasonal
influenza vaccines remains a priority as a result of con-
tinued antigenic drift and shift of the influenza virus [12].
4.1 Limitations
There are some limitations to this study. First, fewer chil-
dren aged 11–17 years were recruited than other age
groups. This is probably due to Public Health England’s
recommended usage of the vaccine [2]. During the
2014/2015 flu season, only ‘‘high risk’’ individuals, i.e.
those at risk of serious illness or death, as defined by the
Department of Health seasonal influenza immunisation
programme specifications [13], and those in pilot area
schools were eligible for vaccination in England. Concerns
from teaching staff and immunisation coordinators about
low vaccine uptake by children and adolescents in schools
may have had a negative impact on their eagerness to
participate in this pilot study. This demographic distribu-
tion pattern may change in subsequent years as the vaccine
is rolled out to more healthy children [2]. Additionally, the
majority of GPs involved in this study vaccinated mostly
children under 6 years old with QLAIV (Fluenz Tetra) and
very few between 6 and 17 years of age. It is unknown
whether adolescents received different influenza vaccina-
tions at these practices. Only a small number of GPs, pri-
mary and high schools were recruited into the study, which
is a result of the desired sample size for the study based on
interim guidance from the EMA [3].
In addition, the number of participants from the same
family was not recorded, and so it is unclear if there may be
clustering of AEIs within families.
Another limitation is that the study focused on the
detection of common AEIs that manifest in the short-term
post-vaccination, which is indicative of increased reacto-
genicity, as laid out in the interim guidance, rather than
uncommon reactions. Other study designs may be more
Table 3 Other symptoms/
events reported captured as free-
text events and presented as
MedDRA preferred term (% of
total other events reported)
System organ class (SOC) PT n (%)
Infections and infestations Nasopharyngitis 2 (5.7)
Tonsillitis 1 (2.9)
Urinary tract infection 1 (2.9)
Hordeolum 1 (2.9)
Influenza 1 (2.9)
Psychiatric disorders Mood altered 1 (2.9)
Nervous system disorders Dizziness 1 (2.9)
Lethargy 1 (2.9)
Migraine 1 (2.9)
Ear and labyrinth disorders Cerumen impaction 1 (2.9)
Ear pain 1 (2.9)
Gastrointestinal disorders Diarrhoea 4 (11.4)
Mouth ulceration 2 (5.7)
Abdominal pain upper 1 (2.9)
Anal inflammation 1 (2.9)
Chapped lips 1 (2.9)
Dysphagia 1 (2.9)
Skin and subcutaneous tissue disorders Pruritus 1 (2.9)
Blister 1 (2.9)
Musculoskeletal and connective tissue disorders Growing pains 1 (2.9)
Reproductive system and breast disorders Vulvovaginal rash 1 (2.9)
General disorders and administration site conditions Fatigue 7 (20.0)
Irritability 1 (2.9)
Adverse drug reaction 1 (2.9)
Total 35 (100.0)
PT preferred term
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appropriate for the detection of rare adverse events. For
example, case-control studies have been used to identify
uncommon adverse events such as Bell’s palsy following
vaccination with inactivated influenza vaccines [14]. Fur-
thermore, the study was not designed to assess causality
between the vaccine and adverse events.
Response rates ranged from 66 to 86 % in this study,
resulting in the potential for non-response bias. However,
the response rate in this study is higher than the reporting
rates of suspected adverse drug reactions in the Yellow
Card Scheme [15].
Finally, the study questionnaires only captured safety
events for those receiving their first dose of QLAIV (Flu-
enz Tetra). It is, however, thought that only a very small
proportion of vaccinees would have received two doses.
The SmPC advises that a second dose should be given after
an interval of at least 4 weeks in children who have not
previously been vaccinated against seasonal influenza [1];
however, the Public Health England Flu Plan specifies that
only children in clinical risk groups aged 2 to\9 years
who have not received an influenza vaccine before should
be offered a second dose of the nasal QLAIV Fluenz Tetra
(given at least 4 weeks apart), which may account for low
numbers receiving a second dose [2].
5 Conclusion
No significant change in reactogenicity or other apparent
safety signal from the data collected has been detected as
part of this study. This study has shown that data can be
generated quickly by gathering vaccinee- or participant-
level feedback following vaccination using both an online
survey and through the use of a well-completed simple
paper questionnaire. Follow-up with participants or their
GP is also possible using this methodology. Continued
enhanced surveillance of seasonal influenza vaccines will
ensure their ongoing safety for the prevention of serious
illness from seasonal influenza outbreaks.
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